Literature DB >> 22509699

[Macular ischemia following intravitreal bevacizumab therapy for diabetic macular edema].

Yosuke Nakamura1, Norio Takeda, Tomoaki Tatsumi, Toshiyuki Oshitari, Miyuki Arai, Yoko Takatsuna, Yoshinori Mitamura, Shuichi Yamamoto.   

Abstract

PURPOSE: To examine the effects of macular ischemia after intravitreal bevacizumab (IVB) in patients with diabetic macular edema(DME).
METHODS: Thirty-three eyes of 33 patients with DME were treated with IVB. Fluorescein angiography (FA) was conducted before and 3 months after IVB, the pretreatment sizes of the foveal avascular zone (FAZ) calculated by FA were compared to the values at 3 months after IVB. This study was approved by the Chiba University Hospital Clinical Research Ethics Committee.
RESULTS: After IVB, the size of the FAZ enlarged significantly (p = 0.03). Among the 33 patients treated with IVB, 2 patients (6%) had advanced macular ischemia with an FAZ enlarged by 50% or more. In both patients, the visual acuity did not worsen and the foveal thickness decreased.
CONCLUSIONS: It is possible that IVB led to macular ischemia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22509699

Source DB:  PubMed          Journal:  Nippon Ganka Gakkai Zasshi        ISSN: 0029-0203


  1 in total

1.  Intravitreal pegaptanib for the treatment of ischemic diabetic macular edema.

Authors:  Christine A Kiire; Rupal Morjaria; Anna Rudenko; Alexina Fantato; Lewis Smith; Amy Smith; Victor Chong
Journal:  Clin Ophthalmol       Date:  2015-12-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.